Update History ▾
October 10, 2026: Initial publication, built from a source-by-source check of the component literature, GHK-Cu copper chemistry, FDA compounding records, the WADA Prohibited List and seller listings for each blend name.
Research-use-only framing applied throughout in line with Remy editorial standards.
TL;DR — Research Summary

GLOW vs KLOW vs Wolverine: all three are seller names for peptide mixtures, not defined compounds. GLOW is commonly listed as GHK-Cu, BPC-157 and TB-500; KLOW is GLOW plus KPV; Wolverine is BPC-157 plus TB-500. Ratios vary by seller, and we found no published study of GLOW or KLOW as a mixture.

Each component has its own literature, almost all of it cell and animal work.[1][2][3] The only combination with published data is the Wolverine pair: in a 2026 rat tendon study, giving both peptides together added nothing over either one alone.[4] Remy Research sells GLOW and BPC-157 + TB-500 blends. It does not sell KLOW, and nothing on this page should be read as saying it does. Material is supplied for in-vitro laboratory research only — not for human or veterinary use.

Compliance note: this page is a research review, not a treatment guide. It does not provide human-use dosing, therapeutic recommendations, or any clinical-use instructions, and should be read in the same non-therapeutic frame required across Remy's research content.

Three Names, One Family of Blends

None of the three names belongs to a regulator, a pharmacopoeia or a manufacturer of record. They are catalogue nicknames that sellers use so buyers can find a mixture, and one seller we checked says so outright on its product page. The amounts below are what sellers commonly list, checked against several listings on October 10, 2026. They are vendor descriptions, not standards, and any batch can differ from its label.

Blend Components, as commonly listed Typical total
GLOW GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg (5:1:1). Other ratios exist, such as 150 + 25 + 25 mg 70 mg (also 200 mg)
KLOW GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg (5:1:1:1) 80 mg
Wolverine BPC-157 + TB-500 at 1:1, as 5 + 5 mg or 10 + 10 mg; also sold as two separate vials 10 or 20 mg

So the three overlap almost completely. GLOW is Wolverine plus GHK-Cu, and KLOW is GLOW plus KPV. In the common 70 and 80 mg versions, GHK-Cu makes up most of the mass. For background on the pair, see BPC-157 vs TB-500; for GLOW itself, the GLOW blend review.

What Each Component Is Studied For

Each ingredient is a separate molecule with its own record. GHK-Cu is the copper complex of the tripeptide Gly-His-Lys, about 402.9 g/mol.[5] KPV is the tripeptide Lys-Pro-Val, 342.4 g/mol.[6] BPC-157 is a 15-residue peptide of about 1419.5 g/mol.[7] TB-500 is the acetylated seven-residue sequence LKKTETQ, residues 17–23 of the 43-residue protein thymosin β4, the part of the protein that binds actin.[8][9]

Component Studied for in the literature Evidence level
GHK-Cu Collagen and gene-expression changes in skin and wound models Cell and animal; few clinical studies
BPC-157 Tendon, muscle, ligament and gut injury models 35 of 36 studies preclinical
TB-500 Actin binding and cell migration in wound models Cell and animal; no human data
KPV NF-κB signalling and colitis models Cell and mouse

A 2018 review gathers the GHK-Cu cell and gene-expression data.[1] A 2025 review of topical GHK-Cu noted a surprising absence of clinical studies.[10] A 2025 systematic review of BPC-157 found 36 studies, 35 of them preclinical, and no clinical safety data.[2] Human trials of thymosin β4 used the full-length protein, for example as eye drops, not the TB-500 fragment.[11] One analytical study suggests that the wound-healing activity reported for TB-500 may come from a breakdown product rather than the parent peptide.[12] Deeper reviews: GHK-Cu and KPV.

What KPV Adds in the Literature

KPV is the C-terminal end of α-melanocyte-stimulating hormone (α-MSH), a 13-amino-acid hormone. Reviewers of α-MSH attribute most of its anti-inflammatory activity to this tripeptide.[13] PubChem files KPV as MSH (11-13).[6]

That is the case for KPV: an anti-inflammatory signal in cells and mouse gut models. No published study has tested what adding KPV does to GHK-Cu, BPC-157 and TB-500. For a side-by-side of KPV against two of the others, see KPV vs BPC-157 vs GHK-Cu.

Has Any Blend Been Studied Together?

Why GHK-Cu Blends Are Blue, and the Sting Reports

The colour comes from copper. GHK binds copper(II) tightly; in solution the metal sits in a flat complex held by three nitrogen atoms of the peptide.[16] Copper(II) complexes like this absorb visible light: Cu(II)–GHK has an absorption band near 606 nm, in the orange-red part of the spectrum, so what passes through looks blue.[17] The more GHK-Cu a mixture contains, the deeper the blue. A GLOW or KLOW blend is mostly GHK-Cu by mass, which is why sellers describe the powder and solution as blue-tinted. Blends without GHK-Cu, such as Wolverine, should not be blue.

Stinging is a frequent user report about GHK-Cu blends such as GLOW and KLOW. We found no published study that measures or explains it, so this page does not offer a cause or a remedy. What the chemistry does show is that the copper complex changes with pH: across pH 3.5 to 10.6 Cu(II)–GHK exists as several different species.[18] Reports of stinging are user observations, not research findings.

Blend pH and Compatibility: Known and Unknown

What is known is mostly about GHK-Cu on its own:

What is not known: we found no published data on how BPC-157, TB-500 or KPV behave next to GHK-Cu in one solution, whether the copper interacts with them, or how long a combined GLOW or KLOW product keeps each component intact. Shelf life for a blend is therefore the manufacturer's claim, not a published result. General storage evidence is in the peptide stability and storage guide.

Reading a Blend COA: Per-Component Amounts, Not One Purity Number

A single "99% purity" line means little for a mixture. A blend certificate should treat each peptide as its own analyte:

GLOW and BPC-157 + TB-500 at Remy Research

Remy Research does not sell KLOW. It lists GLOW and Wolverine-type blends, and KPV and GHK-Cu as single compounds. Product pages are the source of truth for price and stock; the table records the catalogue on October 10, 2026.

Product Composition on the label Documentation
GLOW 70mg pen GLOW 70mg pen: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg Line standard; no independent report
GLOW 200mg pen Genovare GLOW 200mg pen: 150 + 25 + 25 mg Independent testing not supplied
BPC + TB vial Blend vial: 5 + 5 mg Line standard; no independent report
BPC + TB pen Genovare blend pen: 25 + 25 mg Independent testing not supplied
KLOW Not sold. Single-compound KPV and GHK-Cu vials and pens are listed separately —

None of these blends has a published batch-specific report yet, and this page does not imply otherwise. Remy publishes batch reports where they exist in the lab results library. For a format comparison, see GLOW pen vs individual vials and, across all formats, peptide pen vs vial.

Regulatory Status: Facts Only

Status as of October 10, 2026.
  • United States. FDA's page on bulk substances that may present significant safety risks lists BPC-157, GHK-Cu (for injectable routes), KPV and the thymosin β4 fragment LKKTETQ, "also known as TB-500", under "nominated but withdrawn". FDA states it has identified no human exposure data for KPV or the TB-500 fragment, and only limited human data for injectable GHK-Cu.[22]
  • Sport. WADA names BPC-157 in class S0 (non-approved substances) and "thymosin-β4 and its derivatives e.g. TB-500" among growth factors in class S2; both are prohibited at all times.[23] The 2027 List takes effect on January 1, 2027, and names peptides in general in S0.[24][25]
  • United Arab Emirates. This is not a legal opinion; see the Dubai legality brief.

What This Page Does Not Claim

Our Research Standards

This comparison relies on primary literature, PubChem and UniProt records, FDA compounding records and the WADA Prohibited List, each checked on October 10, 2026. Blend compositions are seller descriptions and are labelled as such. No therapeutic, human-use, or veterinary-use claim is made here. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Research

The Remy Research Editorial Board reviews Remy's peptide research library, with a focus on analytical verification, clinical-trial interpretation, and compliance-safe scientific communication.

About the editorial team →

GLOW, KLOW and Wolverine FAQ

GLOW vs KLOW: what is the difference?

KLOW is GLOW with KPV added. GLOW is commonly listed as GHK-Cu, BPC-157 and TB-500, usually 50 + 10 + 10 mg (70 mg); KLOW adds 10 mg of KPV (80 mg). Both are seller names, so ratios vary. KPV has been studied for anti-inflammatory signalling in cell and mouse colitis models.[3]

What is KLOW peptide?

KLOW is a seller name for a four-peptide research blend: GHK-Cu, KPV, BPC-157 and TB-500, most often listed as 50 + 10 + 10 + 10 mg (80 mg). It is not a defined compound and no study has tested the four together. Remy Research does not sell KLOW.

KLOW vs Wolverine: what is the difference?

Wolverine is only BPC-157 plus TB-500. KLOW adds GHK-Cu and KPV to that pair. Wolverine has one published combination study in rats; KLOW has none.

What is the Wolverine peptide blend?

Wolverine is a seller nickname for BPC-157 plus TB-500, usually 1:1, listed as 5 + 5 mg or 10 + 10 mg, or as two separate vials. It is the only one of the three combinations with published combination data: one 2026 rat tendon study, where the pair added no benefit over either peptide alone.[4]

Does Remy Research sell KLOW?

No. Remy Research sells GLOW (a 70mg pen and a Genovare 200mg pen) and BPC-157 + TB-500 blends, and lists KPV and GHK-Cu as single compounds. It does not sell a KLOW product. All material is for in-vitro laboratory research only.

Has GLOW or KLOW been studied in humans?

No. We found no published study of the GLOW or KLOW mixture in cells, animals or people as of October 10, 2026. The evidence that exists is for each component on its own, and it is mostly preclinical.

Why is my GLOW or KLOW blend blue?

Because of the copper in GHK-Cu. The Cu(II)–GHK complex absorbs light near 606 nm, in the orange-red range, so the solution looks blue. Blends without GHK-Cu, such as Wolverine, should not be blue.[17]

Why do people report stinging with GHK-Cu blends?

Stinging is a common user report, but we found no published study that measures or explains it, so we do not offer a cause or remedy. Chemistry studies show the copper complex takes different forms across pH 3.5 to 10.6.[18]

Are BPC-157 and TB-500 banned in sport?

Yes. WADA names BPC-157 in class S0 and thymosin β4 derivatives such as TB-500 in class S2; both are prohibited at all times. The 2027 List, in force from January 1, 2027, names peptides in general in S0.[23][25]

What should a GLOW or KLOW certificate of analysis show?

Separate identity and amount results for each peptide, ideally net mg per component, with mass-spectrometry identity, a lab name, a date and a lot number that matches the product. Check which TB-500 is present: the LKKTETQ fragment or full-length thymosin β4.[9][21]

Sources

  1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi: 10.3390/ijms19071987 · PMID: 29986520 ↩
  2. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. doi: 10.1177/15563316251355551 · PMID: 40756949 ↩
  3. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. doi: 10.1053/j.gastro.2007.10.026 · PMID: 18061177 ↩
  4. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. doi: 10.52312/jdrs.2026.2951 · PMID: 42542926 ↩
  5. National Center for Biotechnology Information. PubChem Compound Summary for CID 71587328, Prezatide copper (GHK-Cu; C14H23CuN6O4+, 402.92 g/mol). Accessed October 10, 2026. pubchem.ncbi.nlm.nih.gov/compound/71587328 ↩
  6. National Center for Biotechnology Information. PubChem Compound Summary for CID 125672, MSH (11-13) (KPV tripeptide; C16H30N4O4, 342.43 g/mol). Accessed October 10, 2026. pubchem.ncbi.nlm.nih.gov/compound/125672 ↩
  7. National Center for Biotechnology Information. PubChem Compound Summary for CID 9941957, BPC-157 (C62H98N16O22, 1419.5 g/mol). Accessed October 10, 2026. pubchem.ncbi.nlm.nih.gov/compound/9941957 ↩
  8. UniProt Consortium. UniProtKB P62328, Thymosin beta-4 (human; mature chain residues 2–44). Accessed October 10, 2026. uniprot.org/uniprotkb/P62328 ↩
  9. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. doi: 10.1016/j.chroma.2012.09.043 · PMID: 23084823 ↩
  10. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts. 2025;15:30071. doi: 10.34172/bi.30071 · PMID: 39963574 ↩
  11. Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-496. doi: 10.1097/ICO.0000000000000379 · PMID: 25826322 ↩
  12. Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033. doi: 10.1016/j.jchromb.2024.124033 · PMID: 38382158 ↩
  13. Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66 Suppl 3:iii52-iii55. doi: 10.1136/ard.2007.079780 · PMID: 17934097 ↩
  14. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. doi: 10.1002/ibd.20334 · PMID: 18092346 ↩
  15. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435 ↩
  16. Hureau C, Eury H, Guillot R, et al. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chemistry. 2011;17(36):10151-10160. doi: 10.1002/chem.201100751 · PMID: 21780203 ↩
  17. Ufnalska I, Drew SC, Zhukov I, et al. Intermediate Cu(II)-Thiolate Species in the Reduction of Cu(II)GHK by Glutathione: A Handy Chelate for Biological Cu(II) Reduction. Inorg Chem. 2021;60(23):18048-18057. doi: 10.1021/acs.inorgchem.1c02669 · PMID: 34781677 ↩
  18. Lau SJ, Sarkar B. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J. 1981;199(3):649-656. doi: 10.1042/bj1990649 · PMID: 7340824 ↩
  19. Laussac JP, Haran R, Sarkar B. N.m.r. and e.p.r. investigation of the interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J. 1983;209(2):533-539. doi: 10.1042/bj2090533 · PMID: 6303307 ↩
  20. Badenhorst T, Svirskis D, Wu Z. Physicochemical characterization of native glycyl-l-histidyl-l-lysine tripeptide for wound healing and anti-aging: a preformulation study for dermal delivery. Pharm Dev Technol. 2016;21(2):152-160. doi: 10.3109/10837450.2014.979944 · PMID: 25384620 ↩
  21. Delcourt V, Garcia P, Chabot B, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023;15(4):458-464. doi: 10.1002/dta.3421 · PMID: 36482504 ↩
  22. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (BPC-157, GHK-Cu for injectable routes, KPV and thymosin beta-4 fragment LKKTETQ, also known as TB-500, listed under "nominated but withdrawn"), page modified April 22, 2026. Accessed October 10, 2026. fda.gov ↩
  23. World Anti-Doping Agency. The Prohibited List (S0 Non-approved substances names BPC-157; S2 growth factors names "Thymosin-β4 and its derivatives e.g. TB-500"; prohibited at all times). Accessed October 10, 2026. wada-ama.org/en/prohibited-list ↩
  24. World Anti-Doping Agency. WADA publishes 2027 Prohibited List (in force January 1, 2027). September 21, 2026. wada-ama.org ↩
  25. U.S. Anti-Doping Agency. Athlete Advisory: What’s New on the 2027 WADA Prohibited List? ("peptides" in general named in S0). October 6, 2026. usada.org ↩

For current stock and price, use the GLOW 70mg pen page. Remy Research does not sell KLOW. For the GLOW evidence in depth, see the GLOW blend review; for the two-peptide blend, the BPC-157 + TB-500 blend guide.